Abstract: The disclosure relates to cyclopropyl derivatives and methods of use. In some embodiments, the disclosure relates to methods of managing medical disorders with pharmaceutical compositions disclosed herein administered to subject in need thereof. In certain embodiments, the disclosure relates to methods of managing mental disorders, mood disorders, pain, and fibromyalgia and related conditions with pharmaceutical compositions disclosed herein.
Type:
Grant
Filed:
May 3, 2016
Date of Patent:
February 19, 2019
Assignees:
Emory University, Wake Forest University Health Services
Inventors:
Huw M. L. Davies, Spandan Chennamadhavuni, Thomas J. Martin, Steven R. Childers
Abstract: Provided herein is a construct comprising, in combination: an EphA3, EphA2 and/or EphB2 binding ligand; and at least one effector molecule. In some embodiments, the at least one effector molecule comprises a therapeutic agent, a nanoparticle, a detectable group, a lipid, or a liposome. In some embodiments, the construct is a fusion protein and/or a covalent conjugate. Further provided is a construct comprising in combination: a ligand that binds to EphA2, EphA3 and/or EphB2; a ligand that binds to IL-13R?2; and at least one effector molecule. Also provided are methods of use thereof for treating cancer.
Type:
Grant
Filed:
November 11, 2014
Date of Patent:
May 22, 2018
Assignee:
Wake Forest University Health Services
Inventors:
Waldemar Debinski, Carla Lema Tome, Sara Ferluga, Poonam S. Sonawane
Abstract: A method of screening for increased risk of fatal prostate cancer in a subject comprises providing a blood sample collected from the subject, and then detecting the presence or absence of an increased level of serum calcium in the sample. An increased level of serum calcium indicates the subject is at increased risk of fatal prostate cancer.
Abstract: The invention is directed to methods for preparing artificial heart valves by preconditioning a matrix seeded with endothelial cells and smooth muscle cells differentiated from isolated progenitor cells. These cell seeded matrices are exposed to fluid conditions that mimic blood flow through the heart to produce tissue engineered heart valves that are analogous to native heart valves.
Abstract: The invention is directed to methods for preparing artificial blood vessels by preconditioning a matrix seeded with endothelial cells to fluid flow conditions that mimic blood flow.
Abstract: The invention pertains to methods of producing artificial composite tissue constructs that permit coordinated motion. Biocompatable structural matrices having sufficient rigidity to provide structural support for cartilage-forming cells and bone-forming cells are used. Biocompatable flexible matrices seeded with muscle cells are joined to the structural matrices to produce artificial composite tissue constructs that are capable of coordinated motion.
Type:
Application
Filed:
March 10, 2006
Publication date:
November 16, 2006
Applicant:
Wake Forest University Health Services
Inventors:
Anthony Atala, James Yoo, Grace Lim, Sang Lee
Abstract: The invention is directed to methods for preparing artificial blood vessels by preconditioning a matrix seeded with endothelial cells to fluid flow conditions that mimic blood flow.
Abstract: The invention is directed to methods for producing a decellularized liver or part of an liver. A decellularized organ is produced using an isolated liver mechanically agitated to remove cellular membranes surrounding the isolated liver without destroying the interstitial structure of the liver. After the cellular membrane is removed, the isolated liver is exposed to a solubilizing fluid that extracts cellular material without dissolving the interstitial structure of the liver. A washing fluid is used to remove the solubilized components, leaving behind a decellularized liver.
Abstract: A composition for improving memory and concentration in mammals with disorders associated with memory impairment. The composition comprises a combination of at least one phytoestrogen and at least one acetylcholinesterase inhibitor such as Huperzine A, or any derivative, analog, metabolite or combination thereof. The composition may further include at least one mammalian estrogen. The method of the invention comprises the co-administration of at least one phytoestrogen and at least one acetylcholinesterase inhibitor in a therapeutically effective amount. Additionally, a mammalian estrogen may be co-administered.
Type:
Grant
Filed:
June 23, 2000
Date of Patent:
February 25, 2003
Assignees:
Wake Forest University Health Services, Morris Notelovitz
Inventors:
Morris Notelivitz, Thomas B. Clarkson, Yuanlong Pan, Mary S. Anthony